CWC27

CWC27 provides the instructions for a protein that is part of the spliceosome, the machinery that edits genetic messages by removing sections called introns before a gene's message can be used. The protein belongs to a family called cyclophilins and is predicted to help other proteins fold into their correct shape. Because splicing is essential in nearly every cell, changes in this gene can affect several body systems, not the eye alone. The condition linked to CWC27 is inherited in an autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.) way, so both inherited copies of the gene must carry a harmful change for a person to be affected. You may also see this gene referred to by the name RPSKA in clinical reports.

The retina is the light-sensing layer at the back of the eye, and CWC27-related disease causes its light-detecting cells, called photoreceptors, to degenerate over time. In one reported patient, poor vision, night blindness (difficulty seeing in dim light), and nystagmus (involuntary eye movements) were present from childhood. Examination of that patient's retina showed widespread thinning and atrophy with scattered greyish pigment deposits and areas of central (macular) atrophy. Imaging with optical coherence tomography (definition: An imaging test (often abbreviated OCT) that creates a detailed, layer-by-layer picture of the retina without touching the eye.), a scan that shows the retina's layers, revealed reduced retinal thickness with loss of key photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) layers. Across reported cases, the retinal picture ranges from isolated retinitis pigmentosa to retinal degeneration accompanying broader syndromic features. Onset of vision symptoms has often been described in early childhood, though the small number of cases means the full range of experiences is not yet clear.

Biallelic (both-copy) loss-of-function changes in CWC27 were first linked to a spectrum of disease in seven unrelated families, ranging from isolated retinal degeneration to severe syndromic forms. Reported systemic features include skeletal anomalies, short stature, short fingers (brachydactyly), craniofacial differences, and neurological defects. Several reports also describe ectodermal involvement such as sparse scalp hair, thin or absent eyebrows and eyelashes, nail changes, dental anomalies, and pigmentary differences of the skin. Additional features described in individual patients include hormonal problems and cataracts, a solitary kidney, a foot bone fusion called tarsal coalition, gait abnormalities, and Hashimoto's thyroiditis. One young child diagnosed with RPSKA also had developmental delay and a brain malformation on MRI. CWC27 has been identified as a cause of inherited retinal disease in genetic testing cohorts, including a study of patients from Mexico. Laboratory and mouse studies confirm that the CWC27 protein acts as a splicing factor, and that its loss in the mouse retina disturbs gene processing and triggers cellular stress.

Because so few patients have been reported, the full range of features, the typical rate of vision change, and long-term outlook are not yet well defined. It is not understood why some people have isolated retinitis pigmentosa while others develop the severe multi-system form, even though both result from changes in the same gene. A mouse study found that Cwc27 is active in the developing inner ear and linked the gene to hearing loss, but whether hearing is affected in people with CWC27 disease is not established from the human reports in this bundle. Clear connections between specific gene changes and specific outcomes have not been established.

As of this review, there is no approved medicine or gene therapy (definition: A treatment that delivers a working copy of a gene into cells to take over for a copy that isn't functioning properly.) that targets CWC27, and one case report notes that management has focused on supportive care such as rehabilitation. In a mouse model, delivering a working copy of the Cwc27 gene into the retina using an AAV viral carrier improved retinal function and reduced photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) loss. This is an encouraging early laboratory result, but it has been tested only in mice and is not an available treatment. Other research has clarified how the CWC27 protein works within the splicing machinery, which may help guide future therapy development.

• First description of CWC27 disease across seven families

  Human genetic study across multiple families, supported by animal models.

  What was found:

  Recessive protein-truncating changes in CWC27 caused a spectrum of disease from isolated retinitis pigmentosa to severe syndromic forms, and mouse models reproduced this variable severity.

  Why it matters:

  This study established CWC27 as a cause of inherited retinal disease and showed that the same gene can produce very different degrees of illness.

  Limitation: The number of families was small, and the mouse findings do not directly predict the course in any individual person.

• Gene replacement therapy tested in mice

  Preclinical animal study.

  What was found:

  Treated eyes showed better retinal function and less photoreceptor degeneration, including of cone cells, than untreated eyes.

  Why it matters:

  It offers early proof-of-concept that gene replacement could one day help this form of retinal degeneration.

  Limitation: This was done only in mice; it does not establish safety, effectiveness, or availability for people.

• How loss of CWC27 harms the retina

  Preclinical mechanistic study in mice.

  What was found:

  Loss of Cwc27 changed how genetic messages were spliced and appeared to trigger a cellular stress response in the retina.

  Why it matters:

  It provides the first in-body evidence of how CWC27 acts as a splicing factor and points to possible disease mechanisms for future treatments.

  Limitation: Mechanisms shown in mice still need confirmation in humans.

• Two siblings and a review of the wider spectrum

  Case report with literature review.

  What was found:

  The report highlighted core features including eye involvement, sparse hair and eyebrows, nail and dental changes, and pigment differences, and added newer findings such as a solitary kidney and thyroid disease.

  Why it matters:

  It broadens the recognized picture of the condition, helping families and clinicians know what other body systems may be involved.

  Limitation: Findings from a few related individuals may not represent everyone with CWC27 variants.

• A newly reported variant expanding the mutation spectrum

  Single-patient case report.

  What was found:

  A novel CWC27 change was identified alongside early-onset retinitis pigmentosa and marked syndromic features including craniofacial differences, short stature, and skin and hair changes.

  Why it matters:

  It adds to the small catalog of known disease-causing variants, aiding future diagnosis of this rare condition.

  Limitation: A single case cannot define how typical these features are.

Unlike isolated retinitis pigmentosa, CWC27 disease can be syndromic, so families may need to watch for and monitor skeletal differences, kidney and thyroid involvement, dental and hair changes, and neurological or developmental concerns. Some children have been diagnosed in the first years of life with developmental delay, which can affect early support and schooling needs. Because the condition is autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.), both parents are typically carriers, and siblings may benefit from genetic counseling to understand their own chances of being carriers or affected.

• Do my specific CWC27 variants suggest an isolated retinal form or a more syndromic form of the condition?
• Which non-eye evaluations (skeletal, kidney, thyroid, hearing, neurological) would you recommend given this diagnosis?
• How often should my vision and retina be monitored, and what changes should prompt an earlier visit?
• What does autosomal recessive inheritance mean for my children, siblings, and other relatives?
• Are there specialists you would involve for the systemic features that can accompany this condition?
• How can I stay informed about research progress specific to CWC27?

Confirming the genetic diagnosis and understanding what the specific variants mean is a helpful first step, and a genetic counselor can explain the testing and its implications for you and your family. Because CWC27 disease can affect more than the eyes, it may be useful to discuss with your care team whether evaluations of the skeleton, kidneys, thyroid, hearing, and neurological development are appropriate. For personalized screening of any current studies, RP Hope's Clinical Trials Finder can be used with CWC27 preselected.